FILED

U.S. COURT OF APPEALS

ELEVENTH CIRCUIT

 APRIL 6, 2010

JOHN LEY

CLERK

[PUBLISH]

IN THE UNITED STATES COURT OF APPEALS

FOR THE ELEVENTH CIRCUIT

________________________

No. 09-10806

________________________

D. C. Docket No. 04-02346-CV-GET-1

ELLEN SCHAAF, 

Plaintiff-Appellant, 

versus

SMITHKLINE BEECHAM CORPORATION, 

d.b.a. GlaxoSmithKline, 

GLAXOSMITHKLINE, 

Defendants-Appellees. 

________________________

Appeal from the United States District Court

for the Northern District of Georgia

_________________________

(April 6, 2010)

Before DUBINA, Chief Judge, BIRCH and BLACK, Circuit Judges.

BLACK, Circuit Judge:
Appellant Ellen Schaaf worked for GlaxoSmithKline as a Regional Vice

President, but, after returning from maternity leave, was demoted to District Sales

Manager. Schaaf then sued GSK, alleging that her maternity leave impermissibly

contributed to her demotion. The district court granted summary judgment on

some of her claims and judgment as a matter of law on others, all in favor of GSK. 

Schaaf appeals these orders; this Court affirms the district court.

I. BACKGROUND

Schaaf worked for GlaxoSmithKline (GSK) first as a Sales Representative

and then as a District Sales Manager (DSM) before assuming the role of Regional

Vice President (RVP) in 1999. In her new role as RVP, Schaaf was tasked with

overseeing a region that included all of Florida and a portion of southern

Georgia—a region that, at the time, had consistently failed to meet GSK’s sales

expectations. Schaaf’s superiors encouraged her to address these shortfalls by

approaching the RVP position with creativity and innovation, and indicated that

the goal of increasing sales volume in the faltering region was of central

importance. After a few years at the helm, the early signs indicated that Schaaf

had successfully risen to the challenge; under her direction, the region’s

performance increased markedly and its sales figures returned to satisfactory

levels.

2
Although initial indications seemed positive, problems between Schaaf and

her subordinates eventually tainted Schaaf’s managerial accomplishments. In July

2002, three DSMs working under Schaaf—Liz Murray, Stewart Miller, and Jose

Castrillo—lodged complaints with the GSK Human Resources (HR) department,

bemoaning Schaaf’s alleged unprofessional management style. HR then

interviewed each of these three DSMs, in addition to all of the other GSK

employees who reported directly to Schaaf. The other employees verified Murray,

Miller, and Castrillo’s initial complaints regarding Schaaf’s management, and, in

some cases, further elaborated on her alleged faults.

The interviews revealed both broad complaints and specific grievances

about Schaaf. For example, the employees complained about Schaaf’s

antagonistic and inflexible management style, chronic inaccessibility, poor

communication skills, harsh and demanding demeanor, and tendency to play

favorites, as well as about her failure to provide written feedback on performance

appraisals, her practice of sharing some DSMs’ confidential performanceevaluation information with other employees, her unwillingness to respond to

voice-mail messages for weeks at a time, and her failure to acknowledge the

contributions of her subordinates. The interviews left no question as to how the

DSMs viewed Schaaf as a supervisor. For instance, one employee lamented the

3
“[t]errible” state of the region’s morale, explaining, “Morale can’t be positive. 

Just no way. You don’t know when she is going to strike. Only thing predictable

is that it’s going to be nasty . . . .” Another reported that Schaaf was simply “not

open to hearing differing viewpoints,” and a third starkly described Schaaf as

“very cold and uncaring.” Schaaf’s subordinates reiterated that Schaaf’s

management defects contributed significantly to the group’s low morale.

After these initial interviews with the subordinates, GSK also interviewed

Schaaf to offer her a chance to respond to their concerns. GSK then determined

that the employees’ grievances were severe and pervasive enough to warrant

taking formal disciplinary action against Schaaf by issuing her a Verbal Warning. 

Lisa Gonzalez, Schaaf’s immediate superior, also instructed Schaaf to complete a

so-called Performance Improvement Plan (PIP) with the goal of bettering her

communication skills and management style. According to GSK, the

improvement plan was designed to allow Schaaf an opportunity to correct her

shortcomings and to foster improved relationships with her subordinates—for

instance, the PIP required Schaaf to issue previously uncompleted written

performance reviews to her subordinates, to attend management-training

programs, and to complete team-building exercises with her subordinates.

4
Incidentally, in July 2002, the same month that Murray, Miller, and Castrillo

first complained to HR, Schaaf informed Gonzalez, her superior, that Schaaf was

pregnant with her fourth child and planned to take maternity leave beginning in

early 2003. As a result, Schaaf expressed some concern regarding her ability to 1

complete the PIP prior to the commencement of her leave. Rather than making a

diligent attempt to satisfy the plan’s requirements and to demonstrate her

willingness to improve herself professionally, however, Schaaf instead ignored

several PIP deadlines, including deadlines to register for the required management

courses and to complete the written performance evaluations. Schaaf even failed

to meet the deadline for simply returning a signed copy of the plan to her

superiors. As a result of this demonstrated unwillingness to cooperate, Schaaf did

not satisfy the PIP’s requirements by the target date of December 5, 2002. 

Gonzalez then extended this time frame until mid-January 2003, and, when Schaaf

likewise failed to meet this new deadline, Gonzalez extended it again until after

Schaaf returned from her maternity leave.

Schaaf began her leave on January 21, 2003. During her absence, an

interim RVP took her place, and the subordinates reported that the region

 Despite the temporal proximity of these events, there is nothing in the record indicating 1

that any of Schaaf’s subordinates knew either that Schaaf was pregnant at the time or that she

planned to take leave a few months later.

5
functioned significantly better while Schaaf was gone. While serving as RVP, the

interim also discovered and corrected several significant administrative problems

that had occurred under Schaaf’s watch, including scores of expense reports that

Schaaf had ignored and several invoices from outside creditors that Schaaf had

failed to pay. The subordinates reported that, under the interim RVP, productivity

had increased, communication had improved, and morale was markedly higher.

Shortly before Schaaf’s return, the DSMs requested a meeting with

Gonzalez, Schaaf’s superior, to express their concerns that the region’s increased

morale and productivity could dissipate immediately if Schaaf resumed her role as

RVP. Gonzalez took these reservations seriously: when Schaaf returned to work

on April 15, 2003, she was immediately instructed to travel to Gonzalez’s office in

North Carolina. Once there, Gonzalez gave Schaaf a choice: she could either

accept a demotion to District Sales Manager or leave the company, but in any case

she would not be reinstalled as RVP. Schaaf eventually accepted the demotion to

DSM, and submitted a request for a written statement of the reasons for her

demotion.

GSK provided the requested written response, in which it informed Schaaf

that her subordinates had complained of her overbearing and hostile management

style and that her region functioned markedly better in her absence. GSK also

6
indicated that Schaaf’s failure to complete the PIP requirements and her

demonstrated unwillingness to change her management behavior contributed to

her demotion. Schaaf then sued, claiming that GSK impermissibly demoted her

for reasons related to her statutorily protected maternity leave.

II. DISCUSSION

Schaaf raises a number of issues on appeal, but her primary arguments

center on whether GSK violated Schaaf’s rights under the Family and Medical

Leave Act (FMLA). Schaaf alleges that GSK violated the statute both by

(1) interfering with her FMLA rights and (2) retaliating against her for exercising

those rights.

The district court granted judgment as a matter of law in GSK’s favor on

both of these claims. On appeal, this Court reviews that grant de novo, and it

draws all reasonable inferences in favor of Schaaf, the nonmoving party. See

Rossbach v. City of Miami, 371 F.3d 1354, 1356 (11th Cir. 2004). The standards

set forth by Federal Rule of Civil Procedure 50 guide the de novo evaluation; that

rule permits a court to “grant a motion for judgment as a matter of law against [a]

party” if it “finds that a reasonable jury would not have a legally sufficient

evidentiary basis to find for the party on that issue.” Fed. R. Civ. P. 50. Granting

such a motion is proper when “the facts and inferences point overwhelmingly in

7
favor of one party, such that reasonable people could not arrive at a contrary

verdict.” Carter v. City of Miami, 870 F.2d 578, 581 (11th Cir. 1989).

While Rule 50 provides the legal standards for determining whether

judgment as a matter of law was appropriate in this case, the FMLA provides the

substantive law under which this Court evaluates Schaaf’s allegations. The

statute’s purpose, among others, is to provide employees with the flexibility

needed to care for a newborn child. To this end, the statute affords eligible

workers up to twelve weeks of unpaid leave per year to attend to the birth and care

of the new child. 29 U.S.C. § 2612(a)(1)(A); Martin v. Brevard County Pub. Sch.,

543 F.3d 1261, 1265 (11th Cir. 2008). Then, when an employee returns from

leave, the FMLA requires that the employer reinstate that employee to the position

she held when her leave began, or to another position that is equivalent in terms of

benefits, pay, and other relevant conditions of employment. § 2614(a)(1); Martin,

543 F.3d at 1267.

Importantly, however, this reinstatement right is not absolute; rather, “an

employer can deny reinstatement if it can demonstrate that it would have

discharged the employee had [s]he not been on FMLA leave.” Martin, 543 F.3d at

1267 (quotations omitted). But, if an employee is not reinstated, the employer

bears the burden of proving that the employee was discharged for independent

8
reasons that were unrelated to the employee’s leave. Parris v. Miami Herald

Publ’g Co., 216 F.3d 1298, 1301 n.1 (11th Cir. 2000).

A. FMLA Interference Claim

Schaaf’s two FMLA claims are similar, as both involve GSK’s decision to

demote her upon her return from FMLA-protected leave. In her first claim, Schaaf

casts her demotion as interference with—that is, denial of—her FMLA rights: the

FMLA entitled Schaaf to reinstatement upon her return, and she was not

reinstated.

To succeed under this interference theory, Schaaf must demonstrate only

that she was “denied a benefit to which [s]he was entitled under the FMLA.” 

Martin, 543 F.3d at 1266–67. Schaaf maintains that she successfully made this

showing by proving that she was demoted upon her return from maternity leave,

thereby establishing that GSK denied her the benefit of reinstatement to which she

was entitled. GSK, on the other hand, contends that it demoted Schaaf for

independent performance-related reasons, and that, consequently, it did not violate

the FMLA.

Neither party disputes that Schaaf made a prima facie showing of an FMLA

interference claim, in that she demonstrated she was not reinstated to the same

position she held prior to taking her FMLA leave. Thus, the crux of this issue is

9
whether GSK proved to a legal certainty that Schaaf was demoted for reasons

unrelated to her FMLA leave, such that she would have been demoted even if she

had not taken leave. See Martin, 543 F.3d at 1267. Because GSK offered

evidence showing that Schaaf was demoted as a result of her ineffective

management style, and Schaaf does not offer any evidence to the contrary, the

district court did not err in granting GSK’s motion for judgment as a matter of law.

Essentially, Schaaf’s arguments rely on one basic premise: because GSK

learned of Schaaf’s hostile temperament, ineffective management practices, and

administrative ineptitude while she was on leave, it follows that GSK would not

have discovered these derelictions had Schaaf not taken maternity leave. Thus,

Schaaf concludes, her maternity leave caused her demotion because, but for the

leave, GSK would have had no reason to demote her.2

This argument, however, is legally incorrect and logically unsound. In an

FMLA interference case, courts examine not whether the FMLA leave was the

but-for cause of an employee’s discharge or demotion, but rather whether it was

the proximate cause. Although this Court has not yet had occasion to address the

familiar distinction between but-for and proximate causation in the FMLA

 Schaaf uses this very language to make her argument; for instance, in her Reply Brief, 2

Schaaf asserts, “[A] jury could find that but-for Ms. Schaaf’s leave, she would not have been

demoted.” Schaaf reiterated this position at oral argument. 

10
context, a brief examination of the statute’s purpose readily illustrates the flaw in

Schaaf’s position.

The purpose of the FMLA is to allow individuals to temporarily put their

careers on hold in order to tend to certain personal matters, like the care of a

newborn child. Its purpose is not to aid an employee in covering up her workrelated deficiencies. If an employee were demoted or discharged for the reason

that she took an FMLA leave, individuals would then be reluctant to take leave to

care for their new children. Thus, because the statute’s purpose would have been

frustrated, it follows that the employee should be able to sue for FMLA

interference and recover damages against the employer. Such a suit also would

have the ancillary benefit of helping to deter other impermissible demotions and

discharges in the future.

On the other hand, the statute’s purpose is not implicated in the least if an

employee’s absence permits her employer to discover past professional

transgressions that then lead to an adverse employment action against the

employee. In such a situation, the employer is motivated not by the taking of the

leave itself, but rather by prior deficiencies that, whenever they were discovered,

would have prompted demotion or discharge whether or not the employee took

FMLA leave. Moreover, future individuals who seek FMLA leave would have no

11
reason to fear demotion or discharge upon their return, unless they, too, had been

professionally deficient.

 Other courts have likewise recognized this distinction. For instance, in a

Seventh Circuit case an employer discovered deficiencies in an employee’s

work while the employee was on FMLA leave. Kohls v. Beverly Enters. Wis., Inc.,

259 F.3d 799, 806 (7th Cir. 2001). That court explained, “The fact that the leave

permitted the employer to discover the problems can not logically be a bar to the

employer’s ability to fire the deficient employee.” Id. There, like here, that the

FMLA leave allowed the employer to uncover prior deficiencies does not mean

that the employee was fired because of the FMLA leave.

The district court for the Northern District of Georgia has applied similar

logic. See Wu v. Se.-Atl. Beverage Corp., 321 F. Supp. 2d 1317 (N.D. Ga. 2004). 

In Wu, the district court explained, “[T]he fact that plaintiff’s leave is what

permitted [the employer] to discover the problems with plaintiff’s work

performance is of no consequence. Although one could say that plaintiff might

not have been demoted if he had not taken leave (at least not at that time), the

leave was not the proximate cause of the demotion.” Id. at 1341.

This distinction between but-for and proximate causation makes good sense

in the FMLA context. Holding that but-for causation is somehow sufficient to

12
support an FMLA claim would permit wanton abuse of the FMLA with perverse

consequences. For instance, Schaaf’s suggested reading of the statute would

effectively protect deficient employees from adverse employment actions, such

that those workers could actually attain job security by seeking leave under the

FMLA. These employees could take leave and actually hope their employers

uncover evidence of their transgressions while they are away. If such evidence

were revealed, the statute would prevent their employer from ever taking adverse

action against them, as the leave would always be the but-for cause of the

discovery of that evidence. Such a laughable result is not supported by policy, by

common sense, or, most importantly, by the statute itself.

Here, the evidence shows that Schaaf was demoted because of managerial

ineffectiveness that revealed itself in full only in her absence; she was not demoted

because (i.e. for the reason that) she took FMLA leave. It does not appear that

Schaaf presented the district court with any evidence to the contrary, and she does

not identify any in her appellate briefs. Accordingly, because “a reasonable jury

would not have a legally sufficient evidentiary basis to find” that Schaaf was

demoted because she took FMLA leave, see Fed. R. Civ. P. 50, the district court

did not err in granting judgment as a matter of law in favor of GSK on Schaaf’s

FMLA interference claim.

13
B. FMLA Retaliation Claim

Schaaf’s second claim likewise centers on the demotion that immediately

followed her return from leave. Under this alternate theory, Schaaf casts her

demotion not as interference with her FMLA rights, but rather as retaliation for

exercising those statutory rights. In essence, Schaaf alleges that she took

leave—an activity protected by the statute—and that she was demoted as a result.

To succeed under this retaliation theory, Schaaf must show that GSK

intentionally “discriminated against [her] because [s]he engaged in activity

protected by the Act.” Strickland v. Water Works & Sewer Bd. of Birmingham,

239 F.3d 1199, 1206 (11th Cir. 2001). Essentially, Schaaf must show that she

suffered an adverse employment action that was “motivated by an impermissible

retaliatory or discriminatory animus.” Id. at 1207.

In an FMLA retaliation case, unless there is direct evidence of the

employer’s retaliatory intent, this Court employs the burden-shifting framework

established by the Supreme Court in McDonnell Douglas Corp. v. Green, 411 U.S.

792, 93 S. Ct. 1817 (1973). Martin, 543 F.3d at 1268. Under the McDonnell

Douglas framework, the plaintiff must first establish a prima facie case by

demonstrating (1) she engaged in statutorily protected activity, (2) she suffered an

adverse employment decision, and (3) the decision was causally related to the

14
protected activity. Id. For the purposes of this analysis, this Court will assume

without deciding that Schaaf has successfully established a prima facie case for

FMLA retaliation: she has shown (1) she took leave to care for her newborn child,

(2) GSK demoted her, and (3) her demotion was temporally proximate to her

leave. See id. (“[T]he close temporal proximity between [the plaintiff’s leave and

her termination] . . . is more than sufficient to create a genuine issue of material

fact of causal connection.”).

Even assuming Schaaf successfully established a prima facie case, however,

this assumption satisfies only the first step of the McDonnell Douglas framework. 

Under this burden-shifting analysis, once Schaaf shows a prima facie retaliation

claim, the burden then shifts to GSK to articulate a legitimate, nondiscriminatory

reason for her demotion. See id. A review of the record indicates GSK has readily

satisfied this burden: GSK produced testimony regarding Schaaf’s poor

management practices, astringent leadership style, and inability to communicate

effectively with her subordinates. GSK then explained that it learned of these

deficiencies while Schaaf was on leave, and accordingly addressed the issue when

Schaaf returned. These performance-related factors indicate that Schaaf’s

demotion was for legitimate reasons unrelated to her FMLA leave; as a result,

15
GSK has satisfied its burden of providing independent, nondiscriminatory bases

for the adverse employment action.

Under McDonnell Douglas, the burden then shifts back to Schaaf to show

that GSK’s supposedly independent reasons were, in reality, merely a pretext for

discrimination. Id. To satisfy this burden, Schaaf must present evidence

“sufficient to permit a reasonable factfinder to conclude that the reasons given by

the employer were not the real reasons for the adverse employment decision.” See

id. (quotations omitted). Ultimately, Schaaf has failed to satisfy this burden.

In alleging that GSK’s reasons were merely pretextual, Schaaf primarily

emphasizes (1) GSK deviated from its disciplinary procedures by demoting Schaaf

rather than issuing her a written warning and (2) a jury could have chosen to

disbelieve GSK’s stated rationale because the company knew of some of Schaaf’s

deficiencies but nevertheless initially intended to reinstate her as RVP upon her

return. None of this evidence, however, demonstrates that GSK’s reasons were

merely a pretext for discrimination.

First, although evidence that GSK deviated from its ordinary disciplinary

procedures may have caused a jury to entertain the possibility of an alternate

explanation for Schaaf’s demotion, Schaaf offered no evidence that would have

16
allowed a jury to find that there was such an alternate explanation. Schaaf did not

3

present any evidence suggesting that GSK was motivated by a discriminatory

animus, nor did she offer any evidence showing that GSK’s reasons were bad

ones—that is, she did not argue that she was not an aggressive, insensitive leader

with poor communication skills. On the whole, GSK showed that it demoted

Schaaf for purely performance-related reasons and, to the extent it deviated from

its disciplinary procedures, it seems to have done so because of the nature of the

situation. Even drawing all inferences in favor of Schaaf, there is nothing on 4

which a reasonable jury could base a finding that GSK demoted Schaaf for

anything other than poor performance.

Schaaf’s second argument—that the jury could have disbelieved GSK’s

nondiscriminatory rationale because the company knew of some of Schaaf’s

deficiencies but initially intended to reinstate her as RVP—is likewise

unpersuasive. That GSK perhaps intended to reinstate Schaaf before learning of

 In applying the McDonnell Douglas burden-shifting analysis in the context of Title VII

3

employment discrimination, this Court has explained that “merely establishing pretext, without

more, is insufficient to support a finding of . . . discrimination. The plaintiff must show he

suffered intentional discrimination because of” a protected ground. See Hawkins v. Ceco Corp.,

883 F.2d 977, 981 n.3 (11th Cir. 1989). Thus, it is insufficient to show merely that an

employer’s reasons are pretextual; rather the plaintiff must show that the reasons are a pretext for

discrimination. In this case, then, even if Schaaf has successfully cast some doubt on GSK’s

nondiscriminatory rationale, she did not show that the rationale was a pretext for discrimination.

 GSK notes that the company’s discipline policy specifically provides the flexibility to 4

deviate from the normal procedures if the circumstances so require.

17
the full extent of her ineffective and oppressive management style only bolsters

GSK’s explanation that the proximate cause of Schaaf’s demotion was

professional ineffectiveness; it in no way indicates that the demotion constituted

impermissible retaliation. Even viewing these events in the light most favorable 5

to Schaaf, there is no contrary inference that a reasonable jury could draw. 

Accordingly, the district court did not err in granting GSK’s motion for judgment

as a matter of law on Schaaf’s FMLA retaliation claim.

III. CONCLUSION

Because a reasonable jury would not have a legally sufficient evidentiary

basis to find in Schaaf’s favor on either of her FMLA claims, the district court did

not err in granting GSK’s motion for judgment as a matter of law.6

AFFIRMED.

 Gonzalez, Schaaf’s superior, testified that she initially intended to bring Schaaf back as

5

RVP following her maternity leave, but that her opinion changed after meeting with the DSMs

on April 1, 2003. Gonzalez explained, “[My opinion changed] [b]ecause I concluded from the

feedback from the managers that Ellen had not shown any change and I didn’t think she had any

intention of showing any change.” This demonstrates not that Gonzalez discriminated against

Schaaf, but, rather, that she permissibly credited the feedback of the DSMs regarding Schaaf’s

professional practices.

 Schaaf raises several other issues on appeal, including the disposition of her claims for 6

pregnancy discrimination and discriminatory discipline, as well as a number of rulings on

evidentiary and sanctions matters. After reviewing the briefs and having had the benefit of oral

argument, this Court holds that these contentions are meritless and it affirms the district court’s

disposition as to each issue.

18